Review on pain reduction when using Golimumab, Tofacilinib and Etanercept
Rheumatology Service, University Hospital Center "Mother Teresa", Tirana, Albania.
Review Article
GSC Advanced Research and Reviews, 2022, 10(03), 159–162.
Article DOI: 10.30574/gscarr.2022.10.3.0084
Publication history:
Received on 13 February 2022; revised on 16 March 2022; accepted on 18 March 2022
Abstract:
Research Background: Biologic drugs are TNF alpha inhibitors, or similar drugs effective in treating AR that do not respond to NSAIDs and DMARDs. They are generally classified as potent drugs in the treatment of Rheumatoid Arthritis, Psoriatic Arthritis and other autoimmune forms of inflammatory arthritis. Biologic drugs are seen as the best way to treat chronic pain that has previously been incurable.
Purpose: To identify the effectiveness of the use of biological drugs in Rheumatoid Arthritis to reduce pain.
Methodology: The methodology that will be used in this study is an observational, cohort study, conducted at the Mother Teresa University Hospital Center in Albania. The sample taken in the study consists of 36 individuals who are currently undergoing biological drug therapy, and in previous treatments have been treated with Methotrexate or NSAIDs. The biological drugs used are Golimumab, Tofacilinib and Etanercept as a change therapy.
Results: The expected results suggest a reduction of pain after the use of biological drugs in the first 6 months of treatment.
Conclusions: Biologic drugs are 70-100% effective in reducing AR pain, mainly joint pain in the small joints of the hands and feet, knee and in advanced stages in the articular pain of the pelvis and spine. A therapeutic approach with biological drugs for patients suffering from chronic pain can improve pain reduction, the patient's daily life, and reduce disability states.
Keywords:
Rheumatoid Arthritis; Biologic drugs; Pain reduction; TNF alpha; Chronic pain
Full text article in PDF:
Copyright information:
Copyright © 2022 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
